Retatrutide

PeptideXpo buyer fit

Overview

Retatrutide (Eli Lilly development code LY3437943) is a 39-amino-acid investigational tri-agonist peptide targeting the GIP, GLP-1, and glucagon receptors. The glucagon-receptor component differentiates Retatrutide from the dual-agonist class (Tirzepatide, Mazdutide, Survodutide) by adding direct hepatic-energy-expenditure modulation on top of the incretin-driven glycemic and weight effects, which is the mechanistic basis for the larger weight-reduction signals observed in Phase 2 trials versus prior best-in-class agents. PeptideXpo supplies lyophilized Retatrutide acetate at ≥99.0% HPLC with batch-specific analytical packet: peak-integration HPLC, ESI mass spec for identity, water content, and counter-ion. Bacterial endotoxin (LAL, USP <85>) and microbial limits (USP <61>/<62>) are available as add-on testing for in vivo workflows and 503A / 503B compounding pharmacy use. Eight standard fill sizes (5 mg through 60 mg) cover both research aliquot scales and dispensing-vial workflows. Bulk pricing tightens significantly at the 100 g and 1 kg break points, Retatrutide aggregate production volumes are lower than for Semaglutide / Tirzepatide, so the per-mg cost curve is steeper but stabilizes once a recurring synthesis route is locked.

Who buys this, and why

Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.

Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.

Specifications

CAS

2381089-83-2

Appearance

White lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

5 mg – 60 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 6 days

MOQ

On request

Lead time

10–18 days

Storage

-20°C, protect from light

Documentation available on request

• Certificate of Analysis (COA)
• HPLC Chromatogram
• Mass-spec identity (ESI-MS)
• Counter-ion / residual solvent
• Bacterial endotoxin (LAL, USP <85>)
• Microbial limits (USP <61>/<62>)
• Stability data on request
• 503A / 503B documentation support

Regulatory note

Investigational compound currently in clinical development; not approved as a finished drug in any jurisdiction. Sold as a bulk active for research and, in markets where regulations permit, for compounding-pharmacy use under the receiving pharmacy's quality system. Buyers are responsible for verifying compounding eligibility against the destination market's current regulatory posture.

Selected literature

1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9.
2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
3. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544.
4. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048.
5. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684.
6. Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q, Lalonde A, Ahmad N, Bethel MA. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026;28(1):83-93.

Frequently asked questions